Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/705535


Czech Republic Pharmaceuticals and Healthcare Report Q1 2009


Description: Czech Republic Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Czech Republic's pharmaceuticals and healthcare industry.

The Czech Republic sits on top of the Business Environment Rankings for Q109 for Central and Eastern Europe. Scoring an equal overall score to neighbouring Slovakia, the Czech market demonstrates a reasonable size by regional standards, high per capita spending and good growth prospects. Despite the negative pricing and reimbursement regulations in the country, sound demographic, political and economic scores mean the country fairs well compared to its regional peers.

Per capita spending on pharmaceuticals reached US$365 in 2008. This signifies the Czech population’s growing access to innovative treatments. Nevertheless, the generics and over-the-counter (OTC) sectors are likely to gain an increased market share in the future, as the government looks to create cost efficiencies within the healthcare system. We have extended our forecasts through to 2013, and forecasts that total drug expenditure will reach US$5.5bn by the end of the forecast period, growing at an average of 5.8% year-on-year (y-o-y) in local currency terms.

Pharmaceutical prices in the Czech Republic are set to significantly decline throughout 2009, as the implementation of pricing and reimbursement reforms will introduce a dual referencing system. The use of jumbo reference groups – which can effectively place patented pharmaceuticals in the same category as similar generic therapeutics – may result in significant reductions for all but the most innovative new products.

The first set of drugs to be referenced were angiotensin-converting enzyme inhibitors (ACEi's) and angiotensin receptor blockers (ARBs), as these classes of drugs have the biggest potential for savings. It is expected that statins, proton-pump inhibitors (PPIs) and H2 receptor antagonists will follow, with all other reference groups due to be included by the end of 2008.

Healthcare fees continue to be the cause of controversy in the political arena, and even led to serious destabilisation of the government’s position following regional elections in the latter part of 2008. The opposition CSSD has threatened to subsidise fees in regional hospitals which could seriously compromise sales of prescription drugs in the outpatient sector.

In late 2008, Health Minister Tomas Julinek began devising further reforms to the healthcare system. Potential changes to the system, likely to be introduced in March 2009, include patients being allowed to seek a second opinion for medical conditions, with costs being covered by the state health insurance and the sale or lease of doctors’ practices. Plans to transform health insurance companies and future university hospitals into joint stock companies have been opposed by opposition parties.


Contents: Executive Summary
Czech Republic Pharmaceuticals And Healthcare Industry SWOT
Czech Republic Political SWOT
Czech Republic Economic SWOT
Czech Republic Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Central And Eastern Europe Pharmaceutical Business Environment Ratings For Q109
Limits To Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Intellectual Property Environment
Pricing And Reimbursement Issues
Healthcare Sector
Hospital Sector
Opposition to Health Fees
Industry Forecast Scenario
Overall Market Forecast
Table: Czech Republic’s Drug Market Forecast Indicators, 2004-2013
Key Growth Factors – Industry
Table: Czech Republic’s Health Expenditure Indicators, 2004-2013
Key Growth Factors – Macroeconomic
Table: Czech Republic – Economic Activity
Prescription Market Forecast
Table: Czech Republic – Prescription Market Indicators, 2004-2013 (US$mn unless otherwise indicated)
Patented Drug Market Forecast
Table: Patented Drugs Market Indicators, 2004-2013
Generics Market Forecasts
Table: Czech Republic’s Generics Market Forecast 2004-2013
OTC Market Forecast
Table: OTC Drugs Market Indicators, 2004-2012 (US$mn unless otherwise stated)
Medical Device Forecast
Czech Republic Medical Device Market Forecast
Export/Import Forecasts
Table: Czech Republic’s Pharmaceutical Trade Indicators, 2004-2013 (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Indicators
Key Risks To Forecast Scenario
Competitive Landscape
Recent Company Developments
Research And Development Sector
Wholesale
Retail Sector
Company Monitor
Multinational Companies
AstraZeneca
Bristol-Myers Squibb
Sanofi-Aventis
Local Companies
Walmark
Zentiva (incorporating Sicomed)
Country Snapshot: Czech Republic Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012
Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Companies Mentioned -AstraZeneca -Bristol-Myers Squibb -Sanofi-Aventis -Walmark -Zentiva (incorporating Sicomed)


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/705535

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 24/11/2009 01:33:28
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Czech Republic Pharmaceuticals and Healthcare Report Q1 2009
Web Address:
http://www.researchandmarkets.com/reports/705535
Office Code:
OC8HJMSMOVUUX

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 24/11/2009 01:33:28

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)